The USPTO is no longer accepting Petitions to Make Special Under the Cancer Immunotherapy Pilot Program. As a result of the success of this program and in order to support the White House’s renewed Cancer Moonshot initiative, the USPTO has implemented the Cancer Moonshot Expedited Examination Pilot Program to provide a broad scope of cancer-related technologies eligible for fast-track review. The new program is an expansion of and replaces the Cancer Immunotherapy Pilot Program, which was launched in 2016 and terminated on January 31, 2023.
The Cancer Immunotherapy Pilot Program provided a fast-track review for cancer immunotherapy-related patent applications without the need for applicant to pay a petition fee or to meet the requirements of the accelerated examination program. Under this pilot program, patent applications pertaining to cancer immunotherapy were advanced out of turn for examination. Patents 4 Patients aimed to cut the review time of patent applications pertaining to cancer immunotherapy in half by issuing final decisions in one year or less after they were received.
Announcements and reports
Contact us
For questions about Patent Center, please contact the Patent Electronic Business Center at ebc@uspto.gov or 866-217-9197.
For questions regarding a specific cancer immunotherapy petition, please contact one of the following:
For questions regarding the Cancer Immunotherapy Pilot Program Federal Register Notice, please contact the Office of Patent Legal Administration at 571-272-7704 or e-mail PatentPractice@uspto.gov.
_____________________________________________________________
NOTE: Some material linked to from this page may require a PDF viewer.
